Gala-diner schreef op 13 juni 2017 22:45:
de conclusies van 144 weken filgotinib in RA:
Based on an observed case analysis 84% (505/601), 65% (389/601), 44% (267/601) and 51% (299/587) of patients reached ACR20, ACR50, ACR70 and DAS28(CRP) remission at Week 60 respectively.
Conclusions: With 1314 patient-years of exposure, the safety profile of filgotinib appears consistent with that of previously reported double-blind studies and the clinical response appears durable
Voor degene die het nog niet zo goed begrijpen...
Abbvie was niet zo slim om Filgotinib te laten aan Gilead.